Vertex Pharmaceuticals (NASDAQ:VRTX) Price Target Raised to $600.00

Vertex Pharmaceuticals (NASDAQ:VRTX) had its price target lifted by Royal Bank Of Canada from $576.00 to $600.00 in a research note published on Tuesday morning,Benzinga reports. The firm currently has an outperform rating on the pharmaceutical company’s stock.

A number of other brokerages have also recently weighed in on VRTX. JPMorgan Chase & Co. began coverage on Vertex Pharmaceuticals in a report on Friday, September 11th. They set an “overweight” rating and a $560.00 price objective on the stock. Truist Financial raised their target price on shares of Vertex Pharmaceuticals from $560.00 to $565.00 and gave the stock a “buy” rating in a report on Wednesday, August 5th. Rothschild & Co Redburn raised their target price on shares of Vertex Pharmaceuticals from $570.00 to $580.00 and gave the stock a “buy” rating in a report on Wednesday, August 5th. TD Cowen lifted their target price on shares of Vertex Pharmaceuticals from $525.00 to $550.00 and gave the stock a “buy” rating in a research report on Wednesday, September 23rd. Finally, Cantor Fitzgerald boosted their price target on shares of Vertex Pharmaceuticals from $595.00 to $619.00 and gave the company an “overweight” rating in a report on Tuesday. One equities research analyst has rated the stock with a Strong Buy rating, twenty-five have assigned a Buy rating and two have assigned a Hold rating to the stock. According to data from MarketBeat.com, Vertex Pharmaceuticals currently has a consensus rating of “Moderate Buy” and a consensus target price of $596.44.

Vertex Pharmaceuticals Stock Performance

Shares of NASDAQ VRTX opened at $542.50 on Tuesday. The company has a quick ratio of 2.74, a current ratio of 2.34 and a debt-to-equity ratio of 0.17. The stock has a market capitalization of $137.69 billion, a price-to-earnings ratio of 34.91, a PEG ratio of 2.84 and a beta of 0.28. The stock’s fifty day simple moving average is $522.81 and its 200 day simple moving average is $481.42. Vertex Pharmaceuticals has a 52-week low of $406.67 and a 52-week high of $568.67.

Vertex Pharmaceuticals (NASDAQ:VRTX) last announced its earnings results on Monday, November 2nd. The pharmaceutical company reported $4.76 EPS for the quarter, missing the consensus estimate of $4.82 by ($0.06). Vertex Pharmaceuticals had a net margin of 30.70% and a return on equity of 21.98%. The company had revenue of $3.44 billion for the quarter, compared to analysts’ expectations of $3.42 billion. During the same period in the prior year, the company earned $4.80 earnings per share. The company’s revenue for the quarter was up 11.8% on a year-over-year basis. As a group, sell-side analysts forecast that Vertex Pharmaceuticals will post 16.50 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the business. Maryland State Retirement & Pension System grew its stake in Vertex Pharmaceuticals by 14.2% during the 3rd quarter. Maryland State Retirement & Pension System now owns 15,568 shares of the pharmaceutical company’s stock valued at $8,139,000 after acquiring an additional 1,941 shares in the last quarter. Ritholtz Wealth Management increased its holdings in shares of Vertex Pharmaceuticals by 5.0% in the 3rd quarter. Ritholtz Wealth Management now owns 4,943 shares of the pharmaceutical company’s stock valued at $2,584,000 after purchasing an additional 234 shares during the period. UNIVEST FINANCIAL Corp lifted its position in shares of Vertex Pharmaceuticals by 140.7% in the third quarter. UNIVEST FINANCIAL Corp now owns 21,785 shares of the pharmaceutical company’s stock worth $11,389,000 after purchasing an additional 12,736 shares in the last quarter. Joel Isaacson & Co. LLC lifted its position in shares of Vertex Pharmaceuticals by 6.8% in the third quarter. Joel Isaacson & Co. LLC now owns 614 shares of the pharmaceutical company’s stock worth $321,000 after purchasing an additional 39 shares in the last quarter. Finally, Jacobi Capital Management LLC boosted its holdings in shares of Vertex Pharmaceuticals by 16.2% during the third quarter. Jacobi Capital Management LLC now owns 1,318 shares of the pharmaceutical company’s stock worth $689,000 after purchasing an additional 184 shares during the period. Hedge funds and other institutional investors own 90.96% of the company’s stock.

Key Stories Impacting Vertex Pharmaceuticals

Here are the key news stories impacting Vertex Pharmaceuticals this week:

• Positive Sentiment: Vertex reported third-quarter revenue of $3.44 billion, up about 12% year over year, and raised its 2026 revenue forecast to $13.15 billion–$13.25 billion. Growth was supported by its cystic fibrosis business and newer products, including CASGEVY. The company also faces a key November 30 FDA decision date for povetacicept in IgA nephropathy. Q3 earnings call highlights
• Positive Sentiment: Multiple analysts raised Vertex price targets or reiterated Buy/Overweight ratings, including Barclays, TD Cowen, JPMorgan, Goldman Sachs, Stifel, Cantor Fitzgerald, RBC, UBS, Wells Fargo, and Scotiabank. The broad positive analyst tone points to confidence in the company’s outlook. Barclays price-target increase
• Positive Sentiment: A longer-term bullish view cited Vertex’s strong position in cystic fibrosis and its gradual expansion into other treatments as reasons it could remain an attractive biotech stock. Long-term outlook
• Neutral Sentiment: Third-quarter revenue exceeded analyst estimates, but earnings per share of $4.76 came in slightly below the $4.82 consensus—an offset to the encouraging sales and guidance update.
• Negative Sentiment: Morgan Stanley lowered its expectations for Vertex’s stock price, offering a counterpoint to the wave of target increases. Morgan Stanley outlook

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals Incorporated is a global biotechnology company focused on developing and commercializing medicines for serious diseases. Founded in 1989 and headquartered in Boston, Massachusetts, the company applies expertise in the science of human disease to discover therapies that address significant unmet medical needs.

Vertex is best known for its cystic fibrosis portfolio, which includes Kalydeco, Orkambi, Symdeko/Symkevi, and Trikafta/Kaftrio. These medicines target the underlying cause of cystic fibrosis for patients with specific mutations in the CFTR gene.